Possibly the dumbest post ever on yahoo message board
Cldn maybe ahead of once with breakthrough designation they can skip p3 and apply for approval with pos.p2 results if I am not mistaken
Not a big enough market for big pharma...unless rindo hs orphan drug status, not sure if it does, if Sao that's could a change the dynamic
exel has good science and still has a decent pipe but the.. debt is very worrisome....888 is too far off and not sure cobi and cabo can save this ...u see what it did to dndn....and they were pulling n 300k a yr off provenge
Dr. Hammers told us that they believe that adding a c-MET inhibitor, as they have done with Cabo, somehow makes the VEGF inhibition work in patients who previously didn’t respond to other treatments like Sutent and Inlyta. That’s one of the reasons that they are trying the drug in lots of cancers where VEGF inhibition had previously been ruled out. So, for a patient who didn’t respond at all to a VEGF inhibitor like Sutent or Votrient as well as to an m-TOR inhibitor such as Afinitor, Cabo would then be a good choice to try. But only after the other drugs had been ruled out. If you responded well to Sutent, but failed after a year or so, Inlyta would still be a better second line choice.....Reading the blog, Chris had some side effects with Cabo, but it was clear it helped extended his QOL PFS and possibly OS.
The biggest promise for PD-1 blockers--both clinically and commercially--likely lies in combination therapies,
in a 35 billion a year field!!
Well Hello...roche pd-1 plus cobimetinib!!!!!
They already discussed recently the approval consideration of more cancer meds based on pfs...we doubled that of prednisone....these patients in comet were able to seek other therapies after pred. This is what destroyed this trial...after comet failed i think the patients were already to far gone and possibly they accepted their fate or too far gone that other therapies were of little use...with additional bone data and other oncologist lobbying for cabo their could be a chance....remember politics is involved in every aspect of life...if the onco's with influence weigh in, it could make a difference.
true this is the future, but I feel encouraged by Dr. Posado's patients where 7of 8 responded.....and where we are questioning if the patients are too advanced...in his trial the most advanced patient did the best!!! its going to be a nail biter to the finish
Not sure if its a retread
Citation: The PLOS ONE Staff (2014) Correction: Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling. PLoS ONE 9(8): e106797. doi:10.1371/journal.pone.0106797
Published: August 21, 2014
Copyright: © 201
Clearly all of the positive energy flowing our way is working its magic. I have not seen Eva with this much energy for more than a year. She is now almost halfway through her second round of the cabozantinib and she is absolutely glowing. The tumour mass on her shoulder continues to shrink, her bloodtests are excellent and even her appetite is starting to increase. She runs rings around the lot of us.